Laura K Ferris

7PUBLICATIONS
32CO-AUTHORS
Toxicology (incl. clinical toxicology)Pharmaceutical delivery technologiesInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 16, 2026
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

|Feb 07, 2025
Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.

Joseph F Merola, Laura K Ferris, Jeffrey M Sobell

|Jul 29, 2024
Resident memory T cells in dirty mice suppress innate cell activation and infiltration into the skin following stimulation with alarmins.

Meaghan E Story, Laura K Ferris, Alicia R Mathers

|Mar 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.

Craig Leonardi, Kristian Reich, Peter Foley

|Mar 20, 2019
Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.

Laura K Ferris, Elyssa Ott, Jingzhi Jiang

Pageof 2

Frequent Collaborators

2 joint publications

Melinda J Gooderham

1 joint publications

A M Secrest

1 joint publications

M-M Chren

1 joint publications

Z H Hopkins